Independent

[flipper44]

It appears DCVax-l may have been discussed (see link below) at the end of June 2025 CHM. You have to read through it twice to figure out that MHRA were answering about 2025 (not 2024). RedRightHand points out NWBO took out a big financing three or four days later at the end of June. If this (end of June CHM) was just before a third RFI was issued, it could push any final decision to Early November, 2025, (90 + 30), aka, when, you guessed it, NWBO would have a minimum of ten year complete survival data for a NICE evidence submission. They also might have, by that time, an initial analysis against another comparable ECA — Survaxm 2b trial control arm. A 91 patient intent to treat control arm (99 patients control arm total).

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176562225

(This feels like some back door way to tell us this was a ten year plan all along.)

On the bright side, we know NWBO and MHRA are still actively engaged with the MAA, we know the Survaxm trial arms have not separated out (not good for Survaxm but probably good for DCVax-l) and Survaxm results are due by midnight August 18, 2025, we know this timing looks and feels like NWBO is dead set on having complete (non-extrapolated) DCVax-l phase iiii ten year plus survival data (aka: early November 2025) for an evidence submission to NICE.

Best wishes to patients in all trials.